Another day, another to-do over Vytorin. Here an investigation. There an investigation. Everywhere an investigation. Still, as interesting as the controversy may be, other matters continue to attract us. It's a big world, after all (look to the left). So here are a few that spun off...
Amgen Posts Anemia Profit On Drop In Anemia Drug Sales (Bloomberg News)
European Panel Doesn't Recommend Celgene's Revlimid (Yahoo/Reuters)
Glaxo To Add Warning To Avandia Label In Europe (Thomson Financial)
Pfizer Launches New Poultry Division (The Poultry Site)
Ranbaxy Seeks Acquisitions To Bolster Indian Market Share (Bloomberg News)